ACHE and Alzheimer disease: Furthermore, according to our kinetic results and confirmed by docking, most of the compounds are dual-site-binding inhibitors of AChE, indicating those compounds as class of potential new anti-Alzheimer agents able to inhibit the formation of toxic AChE–amyloid complexes and consequently positively modify the course of AD.